Clinical outcomes and bleeding events associated with tirofiban combined with intravenous alteplase in acute ischaemic stroke: a retrospective single-center study - Scorecard - MDSpire
Advertisement
Clinical outcomes and bleeding events associated with tirofiban combined with intravenous alteplase in acute ischaemic stroke: a retrospective single-center study
Clinical Scorecard: Outcomes and Hemorrhagic Complications of Tirofiban in Conjunction with Intravenous Alteplase for Acute Ischaemic Stroke: A Retrospective Analysis from a Single Center
At a Glance
Category
Detail
Condition
Acute Ischaemic Stroke (AIS)
Key Mechanisms
Tirofiban inhibits platelet aggregation by blocking GPIIb/IIIa receptor, enhancing thrombolysis with alteplase.
Target Population
Patients with acute ischaemic stroke receiving thrombolysis.
Care Setting
Retrospective observational study in a neurology department.
Key Highlights
Combined therapy resulted in lower NIHSS scores at 24h, 7 days, and 14 days compared to alteplase alone.
Higher rates of favorable 90-day outcomes (mRS ≤ 2) in the combined group.
Increased post-treatment vascular status in the combined group.
Total bleeding rate was 28.89% in the combined group and 17.78% in the alteplase group.
No significant difference in bleeding rates between the two treatment groups.
Guideline-Based Recommendations
Diagnosis
Diagnosis of AIS confirmed by cranial CT or MRI.
Management
Consider tirofiban in conjunction with alteplase for patients with AIS at high risk of re-occlusion.
Monitoring & Follow-up
Monitor neurological status and coagulation parameters post-treatment.
Risks
Evaluate the risk of hemorrhagic complications when using tirofiban with thrombolysis.
Patient & Prescribing Data
90 patients with AIS, aged ≥18 years, with NIHSS scores of 4–25.
Tirofiban may improve outcomes without significantly increasing bleeding risk.
Clinical Best Practices
Adhere to guidelines for thrombolysis in AIS.
Monitor for neurological deficits and bleeding complications post-treatment.
